SCHEMBL7698481

SCHEMBL7698481

O=C(O)Cc1cn(Cc2ccc(Cl)cc2)c2ccccc12

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.77
ALDH1A1 P00352 3/20 0.77
HTR6 P50406 1/20 0.59
PPARD Q03181 2/20 0.58
PPARG P37231 1/20 0.58
PPARA Q07869 1/20 0.58
YES1 P07947 1/20 0.56
KDR P35968 1/20 0.56
JAK3 P52333 1/20 0.56
CDC25A P30304 1/20 0.55
CYP19A1 P11511 2/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
NPSR1 Q6W5P4 2/20 0.54
HDAC1 Q13547 1/20 0.54
HDAC8 Q9BY41 1/20 0.54
HDAC6 Q9UBN7 1/20 0.54
KDM4E B2RXH2 1/20 0.54
MAPT P10636 1/20 0.54
NPY1R P25929 1/20 0.54
HTT P42858 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8178903 0.93 ALDH1A1 (0.67) LMNAALDH1A1HTR6PPARDPPARG
SCHEMBL2051630 0.91 ALDH1A1 (0.80) LMNAALDH1A1HTR6CDC25ACYP19A1
SCHEMBL28785168 0.91 LMNA (0.65) LMNAALDH1A1HTR6PPARDPPARG
SCHEMBL8174654 0.91 LMNA (0.68) LMNAALDH1A1HTR6PPARDPPARG
SCHEMBL1233547 0.88 ALDH1A1 (0.67) LMNAALDH1A1PPARDCDC25ACYP19A1
SCHEMBL4548571 0.88 ALDH1A1 (0.67) LMNAALDH1A1CDC25ASMN1; SMN2HDAC1
SCHEMBL4262388 0.87 ALDH1A1 (0.67) LMNAALDH1A1CDC25AHDAC1HDAC8
SCHEMBL6893171 0.87 LMNA (1.00) LMNAALDH1A1PPARDPPARGPPARA
SCHEMBL20769719 0.86 ALDH1A1 (0.65) LMNAALDH1A1PPARDPPARGPPARA
SCHEMBL13931026 0.85 ALDH1A1 (0.65) LMNAALDH1A1PPARDPPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2002020478-A1 N-BENZYLINDOLE-3-ACETIC ACID DERIVATIVES FOR USE IN THE TREATMENT OF DRUG RESISTAN CANCER DUBLIN CITY UNIVERSITY (IE) 2002-03-14 WO disclosed